Managing side effects of interferon-beta in patients with relapsing- remitting multiple sclerosis

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 883-893

  Munschauer III, Frederick E ^a   Kinkel, Revere Philip ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA INTERFERON; INTERFERON BETA SERINE; PARACETAMOL; RECOMBINANT BETA INTERFERON; STEROID;

ANEMIA; ARTHRALGIA; CHILL; DEPRESSION; DISEASE ACTIVITY; FEVER; FLU LIKE SYNDROME; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; MYALGIA; RELAPSE; REMISSION; REVIEW; TREATMENT OUTCOME;

EID: 0030683529     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80042-2     Document Type: Article

References (14)

1. Jacobs L, Salazar AM, Herndon R, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet. 1986;2: 1411-1413.
2. Jacobs L, O'Malley JA, Freeman A, et al. Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up. Arch Neurol. 1985;42:841-847.
3. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1996; 39:285-294.
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
6. Avonex™. Physicians' Desk Reference®. Montvale, NJ: Medical Economics Company, Inc.; 1997:662-665.
7. Betaseron®. Physicians' Desk Reference®. Montvale, NJ: Medical Economics Company, Inc.; 1997:653-658.
8. Rieckmann P, Weber F, Gunther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996;64:193-200.
9. Rieckmann P, Weber F, Gunther A, Poser S. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon beta-1b treatment in patients with multiple sclerosis. Neurology. 1996;47:604.
10. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1 b for multiple sclerosis: Report of a consensus conference. Neurology. 1996;46:12-18.
11. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. NEJM. 1995;332:1584. Letter.
12. Albani C, Albani G. A case of cutaneous necrosis during interferon-beta (β-IFN) therapy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;62:418. Letter.
13. Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol. 1996;34:365-367.
14. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1 b therapy for multiple sclerosis. Arch Neurol. 1997;54: 531-533.